BioDelivery Sciences International, Inc. (BDSI) Expected to Announce Quarterly Sales of $9.83 Million

Brokerages predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report $9.83 million in sales for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for BioDelivery Sciences International’s earnings, with estimates ranging from $8.99 million to $10.93 million. BioDelivery Sciences International posted sales of $3.93 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 150.1%. The business is expected to announce its next earnings results after the market closes on Friday, March 16th.

On average, analysts expect that BioDelivery Sciences International will report full year sales of $9.83 million for the current year, with estimates ranging from $37.01 million to $60.40 million. For the next fiscal year, analysts anticipate that the business will report sales of $47.29 million per share, with estimates ranging from $42.70 million to $54.67 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow BioDelivery Sciences International.

A number of research firms have weighed in on BDSI. Zacks Investment Research raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Wednesday. Seaport Global Securities began coverage on BioDelivery Sciences International in a research report on Friday, January 26th. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Monday, November 27th. Roth Capital set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Monday, November 13th. Finally, Piper Jaffray Companies set a $4.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Sunday, October 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $4.38.

BioDelivery Sciences International (BDSI) remained flat at $$2.10 during midday trading on Monday. The company had a trading volume of 492,066 shares, compared to its average volume of 535,007. BioDelivery Sciences International has a fifty-two week low of $1.55 and a fifty-two week high of $3.60. The company has a current ratio of 1.28, a quick ratio of 1.07 and a debt-to-equity ratio of 1.89. The firm has a market capitalization of $117.36, a P/E ratio of 23.33 and a beta of 0.50.

In other news, Director Mark A. Sirgo sold 709,502 shares of the stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $2.73, for a total value of $1,936,940.46. Following the completion of the sale, the director now owns 1,759,262 shares of the company’s stock, valued at approximately $4,802,785.26. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mark A. Sirgo sold 162,509 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $2.78, for a total value of $451,775.02. Following the completion of the sale, the director now directly owns 1,759,262 shares of the company’s stock, valued at approximately $4,890,748.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 980,011 shares of company stock valued at $2,666,275. Insiders own 9.00% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BDSI. Northern Trust Corp boosted its holdings in shares of BioDelivery Sciences International by 0.9% in the 2nd quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock valued at $394,000 after buying an additional 1,203 shares during the last quarter. Advisor Group Inc. boosted its holdings in shares of BioDelivery Sciences International by 42.1% in the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 13,341 shares during the last quarter. EAM Investors LLC boosted its holdings in shares of BioDelivery Sciences International by 62.1% in the 3rd quarter. EAM Investors LLC now owns 780,635 shares of the specialty pharmaceutical company’s stock valued at $2,303,000 after buying an additional 299,163 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of BioDelivery Sciences International in the 3rd quarter valued at approximately $116,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of BioDelivery Sciences International by 138.2% in the 3rd quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 20,599 shares during the last quarter. 44.16% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “BioDelivery Sciences International, Inc. (BDSI) Expected to Announce Quarterly Sales of $9.83 Million” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/17/biodelivery-sciences-international-inc-bdsi-expected-to-announce-quarterly-sales-of-9-83-million.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply